Vials of the Pfizer/BioNtech vaccine against the coronavirus disease (COVID-19) are displayed before being used at a mobile vaccine clinic in Valparaiso, Chile, on January 3, 2022.
Rodrigo Garrido | Reuters
Pfizer issued a sales guidance of $67 billion to $71 billion for 2023 on Tuesday, down from record 2022 results.
The drug company booked $100.3 billion for full-year 2022, an all-time high, driven by more than $50 billion in sales of Covid vaccines and antivirals.
Pfizer expects sales for 2023 to fall by as much as 33% compared to 2022 as the pandemic eases and demand for its Covid portfolio falls. The company expects $13.5 billion in 2023 Covid vaccine sales and $8 billion in revenue for Paxlovid.
Pfizer is forecasting earnings of between $3.25 and $3.45 per share for 2023, down 50% from a record $6.58 in 2022. The company reported net income of $31.4 billion in 2022, a 43% increase from 2021.
Pfizer’s stock fell 3% in premarket trading.
The drugmaker’s fourth-quarter results broadly met analysts’ expectations. The company reported net income of nearly $5 billion for the quarter, up 47% from the same period in 2021. It generated revenue of $24.3 billion for the quarter.
Here’s how the company performed versus Wall Street’s expectations for the fourth quarter, based on average analyst estimates compiled by Refinitiv:
Read CNBC’s latest global health coverage:
A mini burger, mini fries and mini beer, Clinton Hall's "Teeny Weeny Mini Meal", is…
After returning to Los Angeles, the Her Friends and Neighbors star shared children Frances19, Molly15,…
Cuba suffered a widespread power outage on March 16, 2026, according to the national electric…
Lights shine on skyscrapers and commercial buildings across the skyline of the City of London,…
The Rivian R2 is on display during the 2025 Los Angeles Auto Show at the…
Shares of Eli Lilly fell 6% on Tuesday and are on track for their worst…
This website uses cookies.